A drug naive parkinsonian patient successfully treated with weak electromagnetic fields

References

• Alexander G. M., Schwartzman R. J., Grothusen J. R., Gordon S. W. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood‐to‐brain transport of levodopa in naive and MPTP parkinsonian monkeys. Neurology 1994; 44: 1491–1499
   PubMed Web of Science ®Google Scholar
• Benton A. L. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968; 6: 53–60
   Web of Science ®Google Scholar
• Bernheimer H., Birkmayer W., Homykiewicz O. Verteilung des 5‐hydroxytryptamins (Serotonin) in Gehirn des Menschen und sein Verhalten bein Patienten mit Parkinson Syndrome. Klinische Wochenschrijr 1961; 39: 1056–1059
   PubMedGoogle Scholar
• Besson M. J., Cheramy A., Feltz P., Clowinshi J. Release of newly synthesized dopamine from dopamine‐containing terminals in the striatum of the rat. Proceedings of the National Academy of Sciences, USA 1969; 62: 741–748
   PubMed Web of Science ®Google Scholar
• Birkmayer W., Riederer P. Die Parkinson‐Krankheii Biochemie, Klinik, Therapie. Springer, Wien 1980
   Google Scholar
• Clark D., White F. J. D1 dopamine receptors‐the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1987; 1: 347–388
   PubMed Web of Science ®Google Scholar
• Coppen A., Metcalfe M., Carroll J. D., Morris J. G. L. Levodopa and L‐tryptophan therapy in parkinsonism. Lancet 1972; 2: 654–657
   Google Scholar
• Davidson D. L. W., Yates C. M., Mawdsley C., Pullar I. A., Wilson H. CSF studies on the relationship between dopamine and 5‐hydroxytryptamine in parkinsonism and other movement disorders. Journal of Neurology Neurosurgery and Psychiatry 1977; 40: 1136–1141
   PubMed Web of Science ®Google Scholar
• Douyon R., Serby M., Klutchko B., Rotrosen J. ECT and Parkinson's disease revisited: a “naturalistic” study. American Journal of Psychiatry 1989; 146: 1451–1455
   PubMed Web of Science ®Google Scholar
• Dray A. Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. Journal of Physiology (Paris) 1981; 77: 393–403
   PubMedGoogle Scholar
• Everett G. M., Borcherding J. W. L‐dopa: effect on concentrations of dopamine, norepinephrine and serotonin in brains of mice. Science 1970; 168: 849–850
   PubMed Web of Science ®Google Scholar
• Fahn S., Snider S., Prasad A. L. N., Lane E., Makadon H. Normalization of brain serotonin by L‐tryptophan in levodopa‐treated rats. Neurology 1975; 25: 861–865
   PubMedGoogle Scholar
• Gehlen W., Muller J. Zur Therapie der Dopa Psychosen mit L‐tryptophan. Deutsche Medizinische Wochenschrift 1974; 99: 457–463
   Google Scholar
• Gershanik O. S., Heikkila R. E., Duvoisin R. C. The role of serotonin neurons in the action of L‐dopa in an animal model of Parkinsonism. Neurology 1979; 29: 553
   Web of Science ®Google Scholar
• Goldstein M., Anagnoste B., Battista A. F., Owen W. S., Nakatani S. Studies of amines in striatum in monkeys with nigral lesions‐the disposition, biosynthesis and metabolites of3−H dopamine and 14C‐serotonin in striatum. Journal of Neurochemistry 1969; 16: 645–653
   PubMed Web of Science ®Google Scholar
• Gumpert E. J. W., Sharpe D. M., Courzon G. Amine metabolites in cerebrospinal fluid in Parkinson's disease and the response to L‐dopa. Journal of Neurological Sciences 1973; 19: 1–12
   PubMed Web of Science ®Google Scholar
• Harik S. I., McGunigal T. The protective influence of the locus ceruleus on the blood brain barrier. Annuls of Neurology 1984; 15: 568–574
   PubMed Web of Science ®Google Scholar
• Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427–442
   PubMed Web of Science ®Google Scholar
• Ishizaki F., Nishikawa S. Relation of blood serotonin and bezylamine oxidase to clinical symptoms and prognosis in Parkinson's disease. European Neurology 1988; 28: 291–294
   PubMed Web of Science ®Google Scholar
• Jenkins R. B., Groh R. H. Mental symptoms in parkinsonian patients treated with L‐dopa. Lancet 1970; 2: 177–180
   PubMed Web of Science ®Google Scholar
• Kaplan E. The process approach to neuropsychological assessment of psychiatric patients. Journal of Neuropsychiatry 1990; 2: 72–87
   PubMedGoogle Scholar
• Karson C. N., Berman K. F., Kleinman J., Karoum F. Seasonal variation in human central dopamine activity. Psychiatry Research 1984; 11: 111–117
   PubMed Web of Science ®Google Scholar
• Kirk A., Kertesz A. On drawing impairment in Alzheimer's disease. Archives of Neurology 1991; 48: 73–77
   PubMed Web of Science ®Google Scholar
• Kolb B., Whishaw I. Q. Fundamentals of human neuropsychology. W. H. Freeman and Company, New York 1990; 455–456; 233–236; 463–501
   Google Scholar
• Kostic V. S., Djuricic B. M., Covickovic‐Sternic N., Bumbasirevic L., Nikolic M., Mrsulja B. B. Depression and Parkinson's disease: possible role of serotonergic mechanisms. Journal of Neurology 1987; 234: 94–96
   PubMed Web of Science ®Google Scholar
• Laihinen A., Rinne U. K. Function of dopamine receptors in Parkinson's disease: prolactin responses. Neurology 1986; 36: 393–395
   PubMed Web of Science ®Google Scholar
• Lehmann J. Tryptophan malabsorption in levodopa‐treated parkinsonian patients. Acta Medica Scandinavica 1973; 194: 181–189
   PubMedGoogle Scholar
• Lezak M. D. Neuropsychological assessmentsecond Edition. Oxford University Press, New York 1983; 404–405
   Google Scholar
• Mann D. M. A., Yates P. O., Hawkes J. The pathology of the human locus ceruleus. Clinical Neuropathology 1983; 2: 1–7
   PubMed Web of Science ®Google Scholar
• Maurizi C. P. A mechanism of mania and the chemistry of dreams: a hypothesis. Southern Medical Journal 1984; 77: 1491–1493
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Rosen J., Leventhal J. Depression, intellectual impairment and Parkinson's disease. Neurology 1981; 31: 645–650
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Cote L., Williams J. B. W. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34: 642–646
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Williams J. B. W., Cote L., Frantz A., Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. American Journal of Psychiatry 1986; 143: 756–759
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Sano M., Williams J. B. W., Cote L. J. The relationship of serotonin to depression in Parkinson's disease. Movement Disorders 1988; 3: 237–244
   PubMed Web of Science ®Google Scholar
• McCance‐Katz E. F., Marek K. L., Price L. H. Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 1992; 42: 1813–1814
   PubMed Web of Science ®Google Scholar
• Meerwaldt J. D. Treatment of hypokinetic rigid syndrome with fluvoxamine maleate. Lancet 1986; 2: 977–978
   Google Scholar
• Miller E. M., Nieburg H. A. L‐tryptophan in the treatment of levodopa induced psychiatric disorders. Diseases of the Nervous System 1974; 35: 20–23
   PubMedGoogle Scholar
• Milner B. Some effects of frontal lobectomy in man. The frontal granular cortex and behavior, J. M. Warren, K. Akert. McGraw‐Hill, New York 1964; 313–334
   Google Scholar
• Mindham R. H. S., Marsden C. D., Parkes J. D. Psychiatric symptoms during L‐dopa therapy for Parkinson's disease and their relationship to physical disability. Psychological Medicine 1976; 6: 23–33
   PubMed Web of Science ®Google Scholar
• Nausieda P., Weiner W. J., Kaplan L. R., Weber S., Klwans H. L. Sleep disruption in the course of levodopa therapy: an early feature of the levodopa psychosis. Clinical Neuropharmacology 1982; 5: 183–194
   PubMed Web of Science ®Google Scholar
• Nausieda P. A., Tanner C. M., Klawans H. L. Serotonergically active agents in levodopa‐induced psychiatric toxicity reactions. Advances in Neurology, S. Fahn, D. B. Calne, I. Shoulson. Raven Press, New York 1983; 37: 23–32
   Google Scholar
• Ng L. K. Y., Chase T. N., Colburn R. W. Release of (3H) dopamine by L‐5‐hydroxytrypotphan. Brain Research 1972; 45: 499–505
   PubMed Web of Science ®Google Scholar
• Osterrieth P. A. Le test de copie dune figure complexe. Archives of Psychology 1944; 30: 206–356
   Google Scholar
• Pazo J. H. Effects of melatonin on spontaneous and evoked neuronal activity in the mesencephalic reticular formation. Bruin Research Bulletin 1979; 4: 725–730
   PubMed Web of Science ®Google Scholar
• Poirier L. J., Singh P., Sourkes T. L., Boucher R. Effect of amine precursors on the concentration of striatal serotonin in cats with and without unilateral brainstem lesions. Brain Research 1967; 6: 654–666
   PubMedGoogle Scholar
• Rabey J. M., Vardi J., Askenazi J. I., Streifer M. L‐tryptophan administration in L‐dopa induced hallucinations in elderly parkinsonian patients. Gerontology 1977; 23: 438–444
   PubMed Web of Science ®Google Scholar
• Ramier A. M., Hecan H. Role respectif des atteintes frontales et de la lateralisation lesionnelle dans les deficits de la “fluence verbale.”. Revue de Neurologie 1970; 123: 17–22
   PubMed Web of Science ®Google Scholar
• Reiter R. J. Changes in circadian melatonin synthesis in the pineal gland of animals exposed to extremely low frequency electromagnetic radiation: a summary of observations and speculation on their implications. Electromagnetic fields and circadian rhythmicity, M. C. Moore‐Ede, S. S. Campbell, R. J. Reiter. Birkhäuser, Boston 1992; 13–27
   Google Scholar
• Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Archives of Psychology 1942; 28: 286–340
   Google Scholar
• Riklan M., Zahn T. P., Diller L. Human figure drawings before and after chemosurgery of the basal ganglia in Parkinsonism. Journal of Nervous and Mental Disease 1962; 135: 500–506
   PubMed Web of Science ®Google Scholar
• Sacks O. W., Kohl M. S., Messeloff C. R., Schwartz W. F. Effects of levodopa in parkinsonian patients with dementia. Neurology 1972; 22: 516–519
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields as a novel therapeutic modality in Parkinson's disease. International Journal of Neuroscience 1992a; 66: 1–15
   PubMed Web of Science ®Google Scholar
• Sandyk R. Magnetic fields in the therapy of parkinsonism. International Journal of Neuroscience 1992b; 66: 209–235
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields in the treatment of Parkinson's disease with the “on‐off” phenomenon. International Journal of Neuroscience 1992c; 66: 97–106
   PubMed Web of Science ®Google Scholar
• Sandyk R. The effects of picotesla range magnetic fields on perceptual organization and visual memory in parkinsonism. International Journal of Neuroscience 1993; 73: 207–219
   PubMed Web of Science ®Google Scholar
• Sandyk R. Reversal of a visuoconstructional deficit in Parkinson's disease by application of external magnetic fields. A report of five cases. International Journal of Neuroscience 1994a; 75: 213–238
   PubMed Web of Science ®Google Scholar
• Sandyk R. Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkinsonian medications. International Journal of Neuroscience 1994b; 74: 191–201
   PubMedGoogle Scholar
• Sandyk R. Improvement in word fluency performance in Parkinson's disease by administration of electromagnetic fields. International Journal of Neuroscience 1994c; 77: 23–46
   PubMedGoogle Scholar
• Sandyk R. Alzheimer's disease: improvement of visual memory and visuoconstructive performance by treatment with picotesla range magnetic fields. International Journal of Neuroscience 1994d; 76: 185–225
   PubMedGoogle Scholar
• Sandyk R. The effects of external picotesla range magnetic fields on the EEG in Parkinson's disease: a follow up study. International Journal of Neuroscience 1994e; 76: 227–229
   PubMedGoogle Scholar
• Sandyk R., Derpapas K. Further observations on the unique efficacy of picotesla magnetic fields in Parkinson's disease. International Journal of Neuroscience 1993a; 70: 233–254
   PubMedGoogle Scholar
• Sandyk R., Derpapas K. The effects of external picotesla range magnetic fields on the EEG in Parkinson's disease. International Journal of Neuroscience 1993b; 70: 85–96
   PubMedGoogle Scholar
• Sandyk R., Fisher H. Serotonin in movement disorders. International Journal of Neuroscience 1988; 42: 185–205
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. L‐tryptophan supplementation in Parkinson's disease. International Journal of Neuroscience 1989; 45: 215–219
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P. Reversal of visual neglect on Parkinson's disease by treatment with picotesla magnetic fields. International Journal if Neuroscience 1993; 73: 93–107
   PubMedGoogle Scholar
• Sandyk R., Anninos P. A., Tsagas N., Derpapas K. Magnetic fields in the treatment of Parkinson's disease. International Journal of Neuroscience 1992; 63: 141–150
   PubMed Web of Science ®Google Scholar
• Sano I., Taniguchi K. L‐5‐hydroxytryptophan (L‐5‐HTP). Therapie des Morbus Parkinson. Munschen Medizinische Wochenschrift 1972; 114: 1717–1719
   PubMedGoogle Scholar
• Scatton B., Dennis T., L'heureux R., Monfort J. C., Duyckaerts C., Javoy‐Agid F. Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Research 1986; 380: 181–185
   PubMed Web of Science ®Google Scholar
• Semm P. Neurobiological investigations on the magnetic sensitivity of the pineal gland in rodents and pigeons. Comparative Biochemistry and Physiology 1983; 76: 683
   Web of Science ®Google Scholar
• Semm P. Pineal function in mammals and birds is altered by earth‐strength magnetic fields. Electromagnetic fields and circadian rhythmicity, M. C. Moore‐Ede, S. S. Campbell, R. J. Reiter. Birkhäuser, Boston 1992; 53–62
   Google Scholar
• Shoulson I., Glaubiger G. A., Chase T. N. On‐off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975; 25: 1144–1148
   PubMed Web of Science ®Google Scholar
• Taylor E. M. The appraisal of children with cerebral deficits. Harvard University Press, Cambridge, Mass 1959
   Google Scholar
• Taylor L. B. Localization of cerebral lesions by psychological testing. Clinical Neurosurgery 1969; 16: 269–287
   PubMedGoogle Scholar
• Thurstone L., Thurstone T. The chicago rests of primary mental abilities. Science Research Associates, Chicago 1943
   Google Scholar
• Welker H. A., Semm P., Willig R. P., Commentz J. C., Wiltschko W., Vollrath L. Effects of an artifical magnetic field on serotonin N‐acetyltransferase activity and melatonin content of the rat pineal gland. Experimental Bruin Research 1983; 50: 426–432
   PubMed Web of Science ®Google Scholar
• Wilson B. W., Anderson L. E., Hilton D. I., Phillips R. D. Chronic exosure to 60‐Hz electric fields: effects on pineal function in the rat. Bioelectromagnetics 1981; 2: 371–380
   PubMed Web of Science ®Google Scholar
• Wilson B. W., Chess E. K., Anderson L. E. 60‐Hz electric field effects on pineal melatonin rhythms. Bioelectromagnetics 1986; 7: 239–242
   PubMed Web of Science ®Google Scholar